DRG Market Assessment reports

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s…

The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (AS), has expanded beyond those with spinal…

The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (AS), has expanded beyond those with spinal…

MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of…

The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…

In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…

Once limited to ankylosing spondylitis (AS), the axial spondyloarthritis (AxSpA) therapy market is undergoing rapid change as the definition of the disease expands beyond those with detectable…

The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…

In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…

Amid Effective TNF-α Inhibitors, What Clinical Improvements Do Rheumatologists and Payers Expect from Emerging Therapies with a Different Mechanism of Action? Axial spondyloarthritis (Ax SpA)…